Topic
Drug Pipeline
Myostatin and activin-pathway drugs — apitegromab, bimagrumab, taldefgrobep, garetosmab, sotatercept, ACE-031 — with the real trial data.
17 articles
FOXO4-DRI Peptide Cycle: Why the Word Does Not Apply
Cycle is bodybuilding vocabulary, and importing it onto a senolytic misdescribes what the compound does. FOXO4-DRI is not anabolic and has no human protocol. Here is the real question underneath the search.
FOXO4-DRI What Is It? A Senolytic, Not an Anabolic
FOXO4-DRI is a synthetic peptide built to kill senescent cells by breaking a protein interaction that keeps them alive. It is not a growth compound, and the difference explains most of the confusion around it.
FOXO4-DRI Before and After: Why No Human Photos Exist
Searching for FOXO4-DRI before and after results turns up images and timelines. None of them document this peptide in a person, because no human has received it in a study. Here is what the real photographed evidence shows.
FOXO4-DRI Side Effects: Unknown in Humans, and Why
No human safety data exists for FOXO4-DRI. What can be said honestly is what the mechanism predicts, what the animal work observed, and where senolysis has already been shown to cause harm.
FOXO4-DRI Benefits: What Senolytics Do to Ageing Muscle
Every claimed FOXO4-DRI benefit traces back to an experiment in a mouse or a dish. Here is each claim set against the study behind it, with the organism named, because that is the column that decides what any of it means.
FOXO4-DRI Protocol: What the Mouse Studies Actually Ran
People searching for a FOXO4-DRI protocol are usually hunting a PDF. No clinical protocol exists. What does exist is the experimental design from the published animal work, which is more informative than the documents circulating online.
FOXO4-DRI Dosage: No Human Dose Exists, and What Does
There is no established human dose for FOXO4-DRI, because no human has ever received it in a registered trial. What does exist is the mouse dosing from the published work, and the vial arithmetic that most people get wrong.
Trevogrumab: The Regeneron Myostatin Blocker Behind COURAGE
Trevogrumab is Regeneron's anti-myostatin antibody. In the COURAGE trial it cut the muscle loss people normally suffer on semaglutide roughly in half, and a three-drug version preserved 81 percent of lean mass. Here is the data, the safety trade-off, and why you cannot buy it.
Sotatercept and the Activin Pathway: Beyond Myostatin
Sotatercept (Winrevair) is an ActRIIA-Fc fusion that started as a muscle drug, became the first activin-signaling inhibitor approved for pulmonary arterial hypertension, and proves that traps in this pathway can save lives outside the muscle field.
Garetosmab and FOP: Regeneron's Activin A Blocker Explained
Garetosmab is Regeneron's activin A antibody for fibrodysplasia ossificans progressiva. Inside the OPTIMA Phase 3 trial, the 94% reduction in new bone lesions, the FDA priority review, and how it ties back to myostatin pathway biology.
Taldefgrobep Alfa: Biohaven's Bet on Muscle-Preserving Weight Loss
Taldefgrobep alfa missed its SMA primary endpoint, but its body-composition data was strong enough to relaunch Biohaven as a contender in the muscle-sparing obesity race. Here is the full status as of May 2026.
ACE-031 (Ramatercept): Why the Original Myostatin Drug Failed
ACE-031 was the first ActRIIB-Fc trap to reach DMD trials. Inside the real Acceleron history, the epistaxis and telangiectasia that ended Phase 2, the ramatercept rename, and why peptide vendors selling 'ACE-031' are not selling the same molecule.
Apitegromab: Scholar Rock's Myostatin Drug for SMA
Apitegromab is the first myostatin-targeted therapy to hit a Phase 3 endpoint in SMA. Here is what SAPPHIRE actually showed, how the drug is dosed, and where FDA review stands in 2026.
Bimagrumab: The Activin Receptor Antibody Lilly Paired With Semaglutide
Bimagrumab is the ActRII antibody Lilly bought for 1.9 billion dollars. Here is the BELIEVE trial data, the JAMA T2DM results, the muscle-spasm problem, and why Lilly hit pause.
Anti-Myostatin Antibodies and Drug Candidates: MYO-029, BMS-986089, LY2495655
Anti-myostatin antibodies include research reagents and clinical drug candidates. This guide explains MYO-029, domagrozumab, BMS-986089, LY2495655, trevogrumab, apitegromab, and what failed trials taught.
Best Myostatin Inhibitor: Ranking Options by Evidence, Not Hype
The best myostatin inhibitor depends on the goal. This evidence-led ranking separates training, creatine, epicatechin, drugs, peptides, and supplement marketing.
Myostatin Inhibitor Drugs: Current Pipeline and Failed Candidates
Myostatin inhibitor drugs are moving through SMA, obesity, and lean-mass trials. This evidence-first update explains apitegromab, bimagrumab, trevogrumab, taldefgrobep alfa, and older failed candidates.